Continuum Advisory’s Novo Nordisk NVO Stock Holding History

Continuum Advisory’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.8K	Buy	+788	New	+$33.9K	﹤0.01%	862
2025 Q2	–	Sell	-5,267	Closed	-$366K	–	1184
2025 Q1	$366K	Sell	5,267 -95	-2%	-$7.85K	0.05%	287
2024 Q4	$461K	Buy	5,362 +40	+0.8%	+$4.33K	0.06%	245
2024 Q3	$561K	Buy	5,322 +1,261	+31%	+$168K	0.07%	231
2024 Q2	$580K	Buy	4,061 +37	+0.9%	+$4.9K	0.08%	208
2024 Q1	$518K	Buy	4,024 +867	+27%	+$103K	0.08%	221
2023 Q4	$327K	Sell	3,157 -89	-3%	-$8.8K	0.05%	354
2023 Q3	$295K	Buy	3,246 +730	+29%	+$64.3K	0.05%	370
2023 Q2	$204K	Buy	+2,516	New	+$206K	0.03%	430

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Continuum Advisory's NVO Position: Q2 2026 in Review

Continuum Advisory opened a new position in Novo Nordisk (NVO) in Q2 2026: 788 shares worth $37.8K. The stake represents ﹤0.01% of the portfolio and ranks #862 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in NVO as recently as Q1 2025.

Continuum Advisory first reported a position in NVO in Q2 2023 and has held it in 9 quarters since. The position peaked at $580K in Q2 2024. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Continuum Advisory held 788 shares of Novo Nordisk worth $37.8K as of Q2 2026.
Novo Nordisk was a new Continuum Advisory position in Q2 2026.
Novo Nordisk made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #862 holding.
Continuum Advisory first reported a position in Novo Nordisk in Q2 2023 and has held it in 9 quarters since.
Continuum Advisory's Novo Nordisk position peaked at $580K in Q2 2024.
1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.